Concepedia

Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China

Xiaoyu Liu, Pengfei Zhang, Chao Li, Xiang Song, Zhaoyun Liu, Wenna Shao, Sumei Li, Xinzhao Wang, Zhiyong Yu

Frontiers in Oncology · 2023 · 20 citations · 24 references

DOIFull text

Open access

Abstract

HER2+ MBC patients pretreated with multiple-line therapies still respond to inetetamab-based treatment. Inetetamab combined with vinorelbine and pyrotinib may be the most effective treatment regimen, with a controllable and tolerable safety profile.

References

24

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2021 · 109.5K citations · Full text

Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer

Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.8K citations

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.7K citations · Full text

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Kimberly Blackwell, Harold J. Burstein, Anna Maria Storniolo et al. · Journal of Clinical Oncology · 2010 · 955 citations · Full text

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

Mark D. Pegram, Sheree Hsu, Gail D. Lewis Phillips et al. · Oncogene · 1999 · 687 citations

, , +10